Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Albumin infusion (25% albumin)
Albumin infusion · 1 trial · 2 indications
Change in fractional excretion of sodium (FENa) with administration of albumin vs placebo
| Arm | Type | Description |
|---|---|---|
| Albumin first | ACTIVE_COMPARATOR | Albumin for one dose, followed by at least 14 day washout period, before crossing over to the alternate arm to receive placebo for one dose. |
| Placebo first | PLACEBO_COMPARATOR | Placebo for one dose, followed by at least 14 day washout period, before crossing over to the alternate arm to receive albumin for one dose. |
| Name | Type | Description |
|---|---|---|
| Albumin infusion (25% albumin) | DRUG | Albumin 25 gram infusion |
| Normal Saline (0.9% NaCl) | DRUG | 100 cc of normal saline |
Inclusion Criteria: * Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration * Serum albumin of \< 3.5 g/dL * Age \>=18 years old Exclusion Criteria: * Patients with GFR \< 30mL/min/1.73 m2 * Changes in or...
Albumin infusion (25% albumin) is an investigational therapy being studied for cirrhosis, specifically for patients with cirrhosis and ascites. It is being evaluated in a Phase 2 clinical trial to assist diuresis in this patient population. The drug is administered as an infusion and is currently in clinical development.
Albumin infusion is being developed by Grifols, S.A., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol GRFS. Grifols is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of Albumin infusion in patients with cirrhosis and ascites.
Albumin infusion is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is recruiting patients with cirrhosis and ascites to assess the drug's ability to assist diuresis in this condition.
Albumin infusion is being studied in a Phase 2 clinical trial with the identifier NCT06812390, titled "Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites." This randomized, double-blind, placebo-controlled trial is recruiting 20 participants in the United States. The study is currently active and enrolling patients aged 18 years and older.
Yes, Albumin infusion is also known as Albumin infusion (25% albumin). The 25% formulation refers to the concentration of albumin in the solution. This formulation is being investigated in the Phase 2 clinical trial for cirrhosis and ascites, where it is administered to assist diuresis.
Albumin infusion is a small molecule therapy that works by supplementing albumin levels in the body. In patients with cirrhosis and ascites, albumin infusion is used to help manage fluid accumulation by assisting diuresis. The trial is biomarker-selected, indicating that patient selection may be based on specific biological markers.